Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:EDGH NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDGH3EDGE Dynamic Hard Assets ETF$35.20+0.3%$34.40$25.70▼$35.71$129.18M-0.0552,031 shs2,881 shsTERNTerns Pharmaceuticals$52.95$49.68$2.65▼$53.19$6.12B-0.374.84 million shs6.35 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDGH3EDGE Dynamic Hard Assets ETF+0.03%+0.37%+2.01%+8.37%+32.98%TERNTerns Pharmaceuticals0.00%+0.04%+0.63%+40.34%+1,650.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDGH3EDGE Dynamic Hard Assets ETF$35.20+0.3%$34.40$25.70▼$35.71$129.18M-0.0552,031 shs2,881 shsTERNTerns Pharmaceuticals$52.95$49.68$2.65▼$53.19$6.12B-0.374.84 million shs6.35 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDGH3EDGE Dynamic Hard Assets ETF+0.03%+0.37%+2.01%+8.37%+32.98%TERNTerns Pharmaceuticals0.00%+0.04%+0.63%+40.34%+1,650.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDGH3EDGE Dynamic Hard Assets ETF 0.00N/AN/AN/ATERNTerns Pharmaceuticals 2.27Hold$55.144.13% UpsideCurrent Analyst Ratings BreakdownLatest AMIF, EDGH, TERN, and BHGU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026TERNTerns Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$58.004/26/2026TERNTerns Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/14/2026TERNTerns Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$44.00 ➝ $44.504/8/2026TERNTerns Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/7/2026TERNTerns Pharmaceuticals William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/31/2026TERNTerns Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$56.00 ➝ $53.003/30/2026TERNTerns Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$56.00 ➝ $53.003/27/2026TERNTerns Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026TERNTerns Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$53.003/27/2026TERNTerns Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDGH3EDGE Dynamic Hard Assets ETFN/AN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$9.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDGH3EDGE Dynamic Hard Assets ETFN/AN/AN/AN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%5/14/2026 (Estimated)Latest AMIF, EDGH, TERN, and BHGU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TERNTerns Pharmaceuticals-$0.30N/AN/AN/AN/AN/A3/30/2026Q4 2025TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEDGH3EDGE Dynamic Hard Assets ETF$0.762.16%N/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDGH3EDGE Dynamic Hard Assets ETFN/AN/AN/ATERNTerns PharmaceuticalsN/A62.4162.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDGH3EDGE Dynamic Hard Assets ETFN/ATERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipEDGH3EDGE Dynamic Hard Assets ETFN/ATERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDGH3EDGE Dynamic Hard Assets ETFN/A3.67 millionN/AN/ATERNTerns Pharmaceuticals40115.52 million113.79 millionNot OptionableAMIF, EDGH, TERN, and BHGU HeadlinesRecent News About These CompaniesStrs Ohio Takes $881,000 Position in Terns Pharmaceuticals, Inc. $TERNMay 8 at 5:52 AM | marketbeat.comTerns Pharmaceuticals (TERN) Projected to Post Earnings on ThursdayMay 7 at 4:05 AM | marketbeat.comMerck completes acquisition of Terns PharmaceuticalsMay 6 at 12:30 PM | pharmabiz.comPMSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion dealMay 6 at 12:30 PM | pharmiweb.comPMerck adds to cancer drug portfolio with new acquisitionMay 5 at 8:33 PM | wfmz.comWMerck Completes Acquisition of Terns Pharmaceuticals, Inc.May 5 at 9:07 AM | businesswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from BrokeragesMay 5 at 2:40 AM | americanbankingnews.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from AnalystsMay 5 at 2:39 AM | marketbeat.comMerck's Keytruda Surge: A Boost Amid Acquisition CostsApril 30, 2026 | devdiscourse.comDMerck still sees ‘compelling’ outlook for Terns leukemia drugApril 30, 2026 | finance.yahoo.comPictet Asset Management Holding SA Boosts Stake in Terns Pharmaceuticals, Inc. $TERNApril 29, 2026 | marketbeat.comOppenheimer downgrades Terns Pharmaceuticals (TERN)April 28, 2026 | msn.comTerns Pharmaceuticals gets FDA breakthrough status for leukemia drugApril 27, 2026 | investing.comTerns Pharmaceuticals Gets Breakthrough Designation for Leukemia TreatmentApril 27, 2026 | marketwatch.comBuy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?April 27, 2026 | zacks.comTerns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from OppenheimerApril 27, 2026 | marketbeat.comTerns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid LeukemiaApril 27, 2026 | globenewswire.comPharma giants see trial wins, EU approvals, and M&A progressApril 24, 2026 | msn.comMerck’s $6.7B Terns deal clears antitrust reviewApril 24, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN)April 21, 2026 | theglobeandmail.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysApril 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThis 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 2026Amazon: Could Globalstar Be the Missing Spark the Stock Needs?By Sam Quirke | April 9, 20263 Low-Volatility ETFs for Peace of Mind in Turbulent TimesBy Nathan Reiff | April 13, 2026PepsiCo Stock Reversal Points Toward New All-Time HighsBy Thomas Hughes | April 16, 2026RPM International's Blowout Quarter Sparks a 15% Rally By Thomas Hughes | April 10, 2026AMIF, EDGH, TERN, and BHGU Company Descriptions3EDGE Dynamic Hard Assets ETF NYSEARCA:EDGH$35.20 +0.12 (+0.34%) As of 10:37 AM EasternThe 3EDGE Dynamic Hard Assets ETF (EDGH) is an exchange-traded fund that mostly invests in target outcome asset allocation. The fund is an actively managed asset allocation fund that invests in various hard assets. The fund seeks capital appreciation and limits losses depending on market conditions. EDGH was launched on Oct 3, 2024 and is issued by 3Edge.Terns Pharmaceuticals NASDAQ:TERN$52.95 0.00 (0.00%) As of 05/5/2026 03:30 PM EasternTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
